Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyoshi, Y.
Right arrow Articles by Noguchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyoshi, Y.
Right arrow Articles by Noguchi, S.
Clinical Cancer Research Vol. 9, 2229-2233, June 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Association of Serum Estrone Levels with Estrogen Receptor-positive Breast Cancer Risk in Postmenopausal Japanese Women1

Yasuo Miyoshi, Yoshio Tanji, Tetsuya Taguchi, Yasuhiro Tamaki and Shinzaburo Noguchi2

Department of Surgical Oncology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan

Purpose: Several reports have demonstrated the association between high serum estrogens levels and breast cancer risk in postmenopausal women. It is hypothesized that breast cancers arising in postmenopausal women with high serum estrogens levels are more likely to be estrogen receptor (ER)-positive. Thus, we have investigated whether or not high serum estrone (E1) levels are associated with ER-positive breast cancer risk in postmenopausal women.

Experimental Design: A case-control study was conducted on 71 cases (postmenopausal breast cancer patients) and 73 controls (postmenopausal healthy women). Serum E1 levels were examined in their association with breast cancer risk after adjustment for the various epidemiological risk factors. In addition, clinicopathological characteristics of breast cancers arising in the women with high E1 levels were investigated.

Results: Women in the high tertile of E1 levels had a significantly (P < 0.01) increased risk of breast cancer as compared with women in the low tertile [odds ratio (OR), 4.14; 95% confidence interval (CI), 1.44–11.87]. Subset analysis according to the ER status showed that women in the high tertile of E1 levels had a significantly increased risk for ER-positive breast cancer (OR, 23.79; 95% CI, 3.50–161.59) but not for ER-negative breast cancer (OR, 1.45; 95% CI, 0.41–5.15) as compared with women in the low tertile. Tumor size and lymph node status were not significantly different between women in the high tertile and those in the intermediate and low tertiles. But the frequency of low-histological-grade tumors and ER-positive tumors (88 and 67%, respectively) showed a greater trend toward an increase (P = 0.06 and P = 0.07, respectively) in women in the high tertile than those (69 and 46%, respectively) in the intermediate and low tertiles. In addition, ER levels in ER-positive tumors were significantly (P < 0.05) higher in women in the high tertile (245.3 ± 37.1 fmol/mg protein) than those in the intermediate and low tertiles (134.0 ± 31.3 fmol/mg protein).

Conclusions: Postmenopausal women with high serum E1 levels have a significantly increased risk for ER-positive, but not ER-negative, breast cancer. Breast cancers arising in women with high E1 levels show a high ER positivity as well as high ER content. Measurement of serum E1 levels would be clinically useful in the selection of postmenopausal women who can benefit from prophylactic use of tamoxifen because tamoxifen can prevent ER-positive, but not ER-negative, breast cancer.




This article has been cited by other articles:


Home page
J. Nutr.Home page
J. Teas, T. G. Hurley, J. R. Hebert, A. A. Franke, D. W. Sepkovic, and M. S. Kurzer
Dietary Seaweed Modifies Estrogen and Phytoestrogen Metabolism in Healthy Postmenopausal Women
J. Nutr., May 1, 2009; 139(5): 939 - 944.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Nagata, Y. Nagao, S. Yamamoto, C. Shibuya, Y. Kashiki, and H. Shimizu
Light Exposure at Night, Urinary 6-Sulfatoxymelatonin, and Serum Estrogens and Androgens in Postmenopausal Japanese Women
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1418 - 1423.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. R. Yang, R. M. Pfeiffer, M. Garcia-Closas, D. L. Rimm, J. Lissowska, L. A. Brinton, B. Peplonska, S. M. Hewitt, R. W. Cartun, D. Mandich, et al.
Hormonal Markers in Breast Cancer: Coexpression, Relationship with Pathologic Characteristics, and Risk Factor Associations in a Population-Based Study
Cancer Res., November 1, 2007; 67(21): 10608 - 10617.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C. Nagata, Y. Nagao, C. Shibuya, Y. Kashiki, and H. Shimizu
Fat Intake Is Associated with Serum Estrogen and Androgen Concentrations in Postmenopausal Japanese Women
J. Nutr., December 1, 2005; 135(12): 2862 - 2865.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.